Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer
暂无分享,去创建一个
[1] L. Buscail,et al. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer , 2020, Nature Reviews Gastroenterology & Hepatology.
[2] F. Balkwill,et al. Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells , 2019, Front. Immunol..
[3] Leaf Huang,et al. Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] Leaf Huang,et al. Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers , 2018, The Journal of Pharmacology and Experimental Therapeutics.
[5] Xuexiang Han,et al. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. , 2018, ACS nano.
[6] Xiao Yang,et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem , 2018, Nature Communications.
[7] A. Singh,et al. Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages , 2018, Scientific Reports.
[8] Lei Zheng,et al. Immune defects in pancreatic cancer. , 2018, Annals of pancreatic cancer.
[9] A. Lau,et al. The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression , 2018, Molecular Cancer Therapeutics.
[10] Xuexiang Han,et al. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. , 2018, Biomaterials.
[11] Leaf Huang,et al. BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma , 2018, Cancer Immunology, Immunotherapy.
[12] E. O’Neill,et al. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. , 2017, Cancer research.
[13] Leaf Huang,et al. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. , 2017, ACS nano.
[14] Jingqin Luo,et al. Tissue‐Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression , 2017, Immunity.
[15] Q. Gao,et al. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells , 2017, Oncoimmunology.
[16] Leaf Huang,et al. Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. , 2017, ACS nano.
[17] Jingqin Luo,et al. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. , 2017, Immunity.
[18] Leaf Huang,et al. Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. , 2016, ACS applied materials & interfaces.
[19] B. Stanger,et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. , 2016, JCI insight.
[20] K. Leong,et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. , 2016, Biomaterials.
[21] Haijun Zhang. Onivyde for the therapy of multiple solid tumors , 2016, OncoTargets and therapy.
[22] Leaf Huang,et al. Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform , 2016, Theranostics.
[23] J. Akada,et al. High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells. , 2015, Anticancer research.
[24] J. Chen,et al. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. , 2015, Biomaterials.
[25] T. Ji,et al. Multiple Layer‐by‐Layer Lipid‐Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models , 2015 .
[26] Gisele Monteiro,et al. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. , 2014, European journal of pharmacology.
[27] R. Wong,et al. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase , 2014, Oncogene.
[28] Yuan Zhang,et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[29] Yuan Zhang,et al. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. , 2013, Biomaterials.
[30] William Y. Kim,et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] Fabien Zoulim,et al. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases , 2013, Nature Reviews Drug Discovery.
[32] William Y. Kim,et al. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. , 2013, Biomaterials.
[33] Chunning Zheng,et al. ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells , 2013, The Journal of international medical research.
[34] Jonathan B. Mitchem,et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.
[35] K. Olive,et al. Genetically engineered mouse models of pancreatic cancer. , 2012, Cancer journal.
[36] Patrick Couvreur,et al. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices , 2011, Nucleic acids research.
[37] P. Couvreur,et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[38] S. Vinogradov,et al. Novel anticancer polymeric conjugates of activated nucleoside analogues. , 2011, Bioconjugate chemistry.
[39] Yu-cheng Tseng,et al. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[40] M. Hidalgo. Pancreatic cancer. , 2010, The New England journal of medicine.
[41] H. Bear,et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. , 2009, International immunopharmacology.
[42] R. Vonderheide,et al. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. , 2009, Cancer letters.
[43] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[44] G. Gallick,et al. GEMCITABINE RESISTANCE IN PANCREATIC CANCER CELLS IS ASSOCIATED WITH INCREASED EXPRESSION OF STEM CELL-LIKE MARKERS AND A CONCOMITANT DOWN-REGULATION OF PTEN AND ACTIVATION OF AKT , 2007 .
[45] D. Tuveson,et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.
[46] R. Ueda,et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.
[47] B. Melichar,et al. Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study , 2003, Expert opinion on pharmacotherapy.
[48] Benjamin Rs. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .
[49] R. Benjamin. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. , 1995, Seminars in oncology.
[50] Y Z Xu,et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.
[51] L. Hertel,et al. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.